Microvascular complications identify a specific coronary atherosclerotic phenotype in patients with type 2 diabetes mellitus.
Coronary artery disease
Diabetes mellitus
Diabetic microvascular complications
Optical coherence tomography
Prognosis
Journal
Cardiovascular diabetology
ISSN: 1475-2840
Titre abrégé: Cardiovasc Diabetol
Pays: England
ID NLM: 101147637
Informations de publication
Date de publication:
15 10 2022
15 10 2022
Historique:
received:
04
07
2022
accepted:
24
08
2022
entrez:
15
10
2022
pubmed:
16
10
2022
medline:
19
10
2022
Statut:
epublish
Résumé
Patients with type 2 diabetes mellitus (T2DM) are considered as a homogeneous cohort of patients. However, the specific role of diabetic microvascular complications (DMC), in determining the features of coronary plaques is poorly known. We investigated whether the presence of DMC may identify a different phenotype of patients associated to specific clinical, angiographic, optical coherence tomography (OCT) features and different prognosis. We prospectively enrolled consecutive T2DM patients with obstructive coronary artery disease (CAD) at their first coronary event. Patients were stratified according to the presence or absence of DMC, including diabetic retinopathy, diabetic neuropathy, and diabetic nephropathy. OCT assessment of the culprit vessel was performed in a subgroup of patients. The incidence of major adverse cardiac events (MACEs) was assessed at follow-up. We enrolled 320 T2DM patients (mean age 70.3 ± 8.8 years; 234 [73.1%] men, 40% acute coronary syndrome, 60% chronic coronary syndrome). Patients with DMC (172 [53.75%]) presented a different clinical and biochemical profile and, of importance, a higher prevalence of multivessel CAD (109 [63.4%] vs. 68 [45.9%], p = 0.002). At OCT analysis, DMC was associated to a higher prevalence of large calcifications and healed plaques and to a lower prevalence of lipid plaques. Finally, MACEs rate was significantly higher (25 [14.5%] vs. 12 [8.1%], p = 0.007) in DMC patients, mainly driven by a higher rate of planned revascularizations, and DMC predicted the occurrence of MACEs (mean follow-up 33.4 ± 15.6 months). The presence of DMC identifies a distinct diabetic population with more severe CAD but with a more stable pattern of coronary atherosclerosis.
Sections du résumé
BACKGROUND
Patients with type 2 diabetes mellitus (T2DM) are considered as a homogeneous cohort of patients. However, the specific role of diabetic microvascular complications (DMC), in determining the features of coronary plaques is poorly known. We investigated whether the presence of DMC may identify a different phenotype of patients associated to specific clinical, angiographic, optical coherence tomography (OCT) features and different prognosis.
METHODS
We prospectively enrolled consecutive T2DM patients with obstructive coronary artery disease (CAD) at their first coronary event. Patients were stratified according to the presence or absence of DMC, including diabetic retinopathy, diabetic neuropathy, and diabetic nephropathy. OCT assessment of the culprit vessel was performed in a subgroup of patients. The incidence of major adverse cardiac events (MACEs) was assessed at follow-up.
RESULTS
We enrolled 320 T2DM patients (mean age 70.3 ± 8.8 years; 234 [73.1%] men, 40% acute coronary syndrome, 60% chronic coronary syndrome). Patients with DMC (172 [53.75%]) presented a different clinical and biochemical profile and, of importance, a higher prevalence of multivessel CAD (109 [63.4%] vs. 68 [45.9%], p = 0.002). At OCT analysis, DMC was associated to a higher prevalence of large calcifications and healed plaques and to a lower prevalence of lipid plaques. Finally, MACEs rate was significantly higher (25 [14.5%] vs. 12 [8.1%], p = 0.007) in DMC patients, mainly driven by a higher rate of planned revascularizations, and DMC predicted the occurrence of MACEs (mean follow-up 33.4 ± 15.6 months).
CONCLUSIONS
The presence of DMC identifies a distinct diabetic population with more severe CAD but with a more stable pattern of coronary atherosclerosis.
Identifiants
pubmed: 36243750
doi: 10.1186/s12933-022-01637-y
pii: 10.1186/s12933-022-01637-y
pmc: PMC9571474
doi:
Substances chimiques
Lipids
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
211Informations de copyright
© 2022. The Author(s).
Références
N Engl J Med. 1993 Sep 30;329(14):977-86
pubmed: 8366922
Diabetes Care. 2021 Jan;44(Suppl 1):S151-S167
pubmed: 33298422
Diabetes Metab Syndr. 2021 Sep-Oct;15(5):102241
pubmed: 34390975
Circulation. 2016 Jun 14;133(24):2459-502
pubmed: 27297342
J Am Coll Cardiol. 2007 Sep 4;50(10):933-9
pubmed: 17765119
N Engl J Med. 2016 Nov 10;375(19):1834-1844
pubmed: 27633186
Diabetes Care. 2021 Jan;44(Suppl 1):S15-S33
pubmed: 33298413
Cardiovasc Diabetol. 2021 May 7;20(1):102
pubmed: 33962619
Circ Cardiovasc Imaging. 2016 Jan;9(1):
pubmed: 26743463
Vasc Health Risk Manag. 2008;4(5):1061-8
pubmed: 19183753
J Am Coll Cardiol. 2019 May 14;73(18):2253-2263
pubmed: 31072568
Eur Heart J. 2021 Apr 7;42(14):1289-1367
pubmed: 32860058
JACC Cardiovasc Imaging. 2018 Jan;11(1):127-142
pubmed: 29301708
J Am Coll Cardiol. 2017 May 23;69(20):2502-2513
pubmed: 28521888
Atherosclerosis. 2011 Sep;218(1):13-8
pubmed: 21763654
N Engl J Med. 2020 Aug 27;383(9):846-857
pubmed: 32846063
Arterioscler Thromb Vasc Biol. 2017 Feb;37(2):191-204
pubmed: 27908890
Clin Exp Pharmacol Physiol. 2011 Feb;38(2):94-101
pubmed: 21143620
J Diabetes Res. 2016;2016:6809703
pubmed: 27547766
Eur Heart J. 2018 Jan 7;39(2):119-177
pubmed: 28886621
J Physiol. 2019 Jan;597(1):193-209
pubmed: 30324679
Eur Heart J. 2020 Jan 7;41(2):255-323
pubmed: 31497854
Atherosclerosis. 2014 Apr;233(2):467-477
pubmed: 24530781
Diabetes Care. 2006 Nov;29(11):2528-38
pubmed: 17065698
Circulation. 2017 Sep 19;136(12):1155-1166
pubmed: 28923905
N Engl J Med. 2013 May 23;368(21):2004-13
pubmed: 23697515
Nat Rev Cardiol. 2022 Oct;19(10):684-703
pubmed: 35449407
Circ Res. 2018 Feb 16;122(4):624-638
pubmed: 29449364
J Am Coll Cardiol. 2018 Jan 23;71(3):339-351
pubmed: 29348027
Circ Res. 2002 Jul 12;91(1):9-16
pubmed: 12114316
Diabetes Care. 2022 Apr 1;45(4):766-768
pubmed: 35349658
Vasc Health Risk Manag. 2008;4(3):575-96
pubmed: 18827908
Circ Res. 2016 May 27;118(11):1808-29
pubmed: 27230643
Diabetes Care. 1999 Jul;22(7):1220
pubmed: 10388997
Eur Heart J. 2020 Jan 14;41(3):407-477
pubmed: 31504439
Circ Res. 2019 Jan 4;124(1):150-160
pubmed: 30605419
Cardiovasc Diabetol. 2021 Jan 7;20(1):9
pubmed: 33413392
Circulation. 2022 May 31;145(22):1632-1641
pubmed: 35603600
Diabetes Res Clin Pract. 2020 Dec;170:108484
pubmed: 33031843
Eur Heart J Cardiovasc Imaging. 2020 Dec 1;21(12):1421-1430
pubmed: 31848590
Circulation. 2005 Mar 29;111(12):1551-5
pubmed: 15781733
World J Diabetes. 2014 Aug 15;5(4):444-70
pubmed: 25126392
Lancet Diabetes Endocrinol. 2016 Jul;4(7):588-97
pubmed: 27216886